LINDA A. JOHNSONTRENTON, N.J. (AP) ¿ The burst of drugmaker mergers announced in the first quarter is worth nearly 50 percent more than all the industry deals announced in 2008, according to a new report. Deals in the quarter had a combined value of $166 billion, more than 10 times the value of deals announced in last year's first quarter and well over the $114 billion in deals announced in all of 2008. That's according to a report released Monday by The Mergermarket Group of New York and London. First-quarter deals include three involving the 10 largest drugmakers. The Roche Group bought the 44 percent of Genentech Inc. it didn't already own for $47 billion. Pfizer Inc. is buying Wyeth for $64 billion and Merck & Co. is buying Schering-Plough Corp. for $43 billion. Those deals are set to close in the fourth quarter. Other sizable deals announced from January through March include Abbott Laboratories buying Advanced Medical Optics Inc. for $2.8 billion, including debt, and Gilead Sciences Inc. buying CV Therapeutics Inc. for $1.4 billion.